<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02231268</url>
  </required_header>
  <id_info>
    <org_study_id>533.2</org_study_id>
    <nct_id>NCT02231268</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess a 6-months Treatment With Gladem</brief_title>
  <official_title>Observational Study Via Internet to Assess a 6-months Treatment With GLADEM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      -  Evaluation of a 6-months treatment with Gladem

        -  Experiences with the internet for performing a postmarketing study (PMS) trial
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Scale (HAMD-6)</measure>
    <time_frame>3 months, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy on a 4-point scale</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of compliance on a 4-point scale</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability on a 4-point scale</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression score</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders</measure>
    <time_frame>up to 6 months</time_frame>
    <description>&gt;= 50 % reduction in HAMD-6 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAMD subscores</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse drug reactions</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">546</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Depressive patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gladem</intervention_name>
    <arm_group_label>Depressive patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        out-patients
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women at least 18 years old

          -  De novo prescription of Gladem

          -  Treatment with Gladem intended for at least 6 months

          -  Depressive disorders

        Exclusion Criteria:

          -  Known hypersensitivity against sertraline

          -  Concomitant treatment with monoamine oxidase (MAO)-inhibitors, selegiline, moclobemide
             (washout for at least 14 days necessary)

          -  Concomitant treatment with other serotoninergic substances like tryptophan or
             fenfluramine

          -  Instable epilepsy

        According to product information (October 1998) Gladem prescription was possible with
        precautions in the following cases:

          -  Patients with stable epilepsy

          -  Patients with restricted liver functions

          -  Suicidal patients

          -  Patients in emotional state and marked sleeping disorders

        According to product information (October 1998) Gladem should only be prescribed during
        pregnancy and lactation period, if the expected benefit was greater than the risk. Women of
        childbearing age should use Gladem only in combination with sufficient contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2014</study_first_posted>
  <last_update_submitted>September 2, 2014</last_update_submitted>
  <last_update_submitted_qc>September 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

